Production of Purified MRSAcin from Local Clinical Strain of Methicillin-Resistant Staphylococcus aureus and Its Applicability as Antimicrobial and Anti-inflammatory of Wounds


Inventor: Teacher Dr. Mais Emad Ahmad/Department of Biology, College of Science, University of Baghdad, Muna Turkey Mossa AL-Mossawei/Department of Biology, College of Science for Women, University of Baghdad, Ahmed Qassim Al-Awadi/Department of Pathology, College of Veterinary Medicine, University of Baghdad



The current proposal patent includes production and purification of a new type of bacteriocin called MRSAcin from local isolates of Methicillin-Resistant Staphylococcus aureus (MRSA) isolated from different clinical specimens including burns, wounds, urin in addition to nose and ear swabs from hospital reviewers patients. The most potent isolates of MRSAcin production were screened. The optimal conditions for product were identified, the selection, purification and characterization of production was identified, the best method was determined for measuring its laboratory inhibitory activity against pathogens, and the minimum inhibitory concentration (MIC) against pathogen was tested. Antibiotic resistant bacteria and yeast, and its resistance to a range of temperature and pH, as well as its stability testing when treated with a number of ionic detergents, organic solvents and protein soluble enzymes, also studied its effect on the permeability of bacterial cells, its application as antibacterial and anti-inflammatory wound infections in a mouse animal model against the same MRSA isolate and Pseudomonas aeruginosa, as Gram negative bacteria. The results showed that MRSAcin showed a clear effect against many pathogens by observing the diameters in the well diffusion assay. The MIC was 62.5 μg/ml, and its molecular weight was 15 kg dalton in the gel filtration chromatography , and it had a membrane-positive effect against Gram positive and negative bacteria. In vitro and in vivo laboratory efficiency was demonstrated by mice when used as liquid drops in the treatment of experimentally contaminated wounds with MRSA itself and P. areuginosa. The speed of healing of these wounds compared to untreated contaminated wounds was observed.